Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +10 vs. previous quarter
- 173
- 13F valueReported value at the end of Q2 2026
- $1.06B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CRVS, Q2 2026
No superinvestor reported holding CRVS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Corvus Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Moore David ScottDirector | PPurchase | +21.7K | $11.53 | +$250.2K | New position21.7K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Miller Richard A MDPresident and CEO | PPurchase | +6.93K | $12.04 | +$83.5K | +0.6%1.20M after | 2 lots |
| Jul 1, 2025 (view filing)9:23 PM ET | Jun 27 | 4 days | OrbiMed Advisors LLC and 1 otherDirector, 10% Owner | SSale | −1.18M | $4.16 | −$4.89M | −14.1%7.17M after | |
| Jul 1, 2025 (view filing) | Jun 27 | 4 days | Thompson Peter A.Director, 10% Owner | SSale | −1.18M | $4.16 | −$4.89M | −14.1%7.17M after | |
| May 8, 2024 (view filing)8:28 PM ET | May 6 | 2 days | OrbiMed Advisors LLC and 1 otherDirector, 10% Owner | PPurchase | +2.84M | $1.73 | +$2.50M | –1.40M after | Derivative2 lots |
| May 8, 2024 (view filing) | May 6 | 2 days | Thompson Peter A.Director, 10% Owner | PPurchase | +2.84M | $1.73 | +$2.50M | –1.40M after | Derivative2 lots |
| May 7, 2024 (view filing) | May 6 | 1 day | Jones William BentonSee Remarks | PPurchase | +20.0K | $1.73 | +$34.6K | +15.0%153.8K after | |
| May 7, 2024 (view filing) | May 6 | 1 day | Jones William BentonSee Remarks | PPurchase | +19.4K | – | – | –19.4K after | Derivative |
| May 7, 2024 (view filing) | May 6 | 1 day | Miller Richard A MDPresident and CEO | PPurchase | +577.6K | $1.73 | +$999.3K | New position577.6K after | |
| May 7, 2024 (view filing) | May 6 | 1 day | Miller Richard A MDPresident and CEO | PPurchase | +559.1K | – | – | –559.1K after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Corvus Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 7,165,006 | $107.0M | 2.03% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,138,811 | $106.7M | 0.00% | +978,389+15.9% | Added |
| State Street Corp | 4,474,091 | $66.8M | 0.00% | +908,099+25.5% | Added |
| Price T Rowe Associates Inc | 3,789,126 | $56.6M | 0.01% | +871,826+29.9% | Added |
| Vanguard Capital Management LLC | 3,292,710 | $49.2M | 0.00% | +58,172+1.8% | Added |
| Adams Street Partners LLC | 3,275,616 | $48.9M | 11.06% | 00.0% | Unchanged |
| Vivo Capital, LLC | 2,805,816 | $41.9M | 3.83% | 00.0% | Unchanged |
| Wellington Management Group LLP | 2,731,632 | $40.8M | 0.01% | +413,115+17.8% | Added |
| Perceptive Advisors LLC | 2,667,441 | $39.9M | 0.62% | +375,000+16.4% | Added |
| Deep Track Capital, LP | 2,491,939 | $37.2M | 0.55% | +4000.0% | Added |